Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial
暂无分享,去创建一个
R. Schlenk | A. Ganser | T. Brümmendorf | K. Götze | W. Hofmann | L. Trümper | M. Lübbert | U. Germing | R. Haas | A. Giagounidis | U. Platzbecker | G. Büsche | F. Nolte | D. Haase | J. Schanz | A. Letsch | P. Schafhausen | G. Bug | U. Bacher | K. Shirneshan | F. Braulke | E. Schuler | X. Schulz
[1] A. Trumpp,et al. Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure. , 2016, Blood.
[2] R. Schlenk,et al. Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5) , 2016, Leukemia.
[3] Mario Cazzola,et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.
[4] R. Schlenk,et al. Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS) , 2016, Leukemia.
[5] A. Stamatoullas,et al. Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion. , 2016, Blood.
[6] F. Solé,et al. Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group , 2015, Haematologica.
[7] Ji‐Hyun Lee,et al. Subsequent Primary Malignancies Among Myelodysplastic Syndrome Patients Treated with or without Lenalidomide , 2014 .
[8] A. Ganser,et al. Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study , 2014, European journal of haematology.
[9] B. Skikne,et al. Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS , 2013, Leukemia.
[10] R. Schlenk,et al. Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic study. , 2013, Leukemia research.
[11] L. Shaffer,et al. Title: ISCN 2013: An International System For Human Cytogenetic Nomenclature (2013)Recommendations Of The International Standing Committee On Human ... 'The Normal Human Karyotype G- And R-bands' , 2013 .
[12] Luca Malcovati,et al. Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.
[13] C. Steidl,et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] M. Cazzola,et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. , 2011, Blood.
[15] Eva Hellström-Lindberg,et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] C. Steidl,et al. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q , 2011, Leukemia.
[17] L. Trümper,et al. FISH analysis of circulating CD34+ cells as a new tool for genetic monitoring in MDS: verification of the method and application to 27 MDS patients. , 2010, Leukemia research.
[18] P. Woll,et al. Persistent malignant stem cells in del(5q) myelodysplasia in remission. , 2010, The New England journal of medicine.
[19] M. Gordon. Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion , 2008 .
[20] Thomas H Müller,et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. , 2007, Blood.
[21] M. Gordon. Efficacy of Lenalidomide in Myelodysplastic Syndromes , 2006 .
[22] Jean McGowan-Jordan,et al. ISCN 2013 : an international system for human cytogenetic nomenclature (2013) : recommendations of the International Standing Committee on Human Cytogenetic Nomenclature , 2005 .
[23] B. Cheson,et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. , 2000, Blood.
[24] T Hamblin,et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.
[25] W. Hiddemann,et al. Evidence for malignant transformation in acute myeloid leukemia at the level of early hematopoietic stem cells by cytogenetic analysis of CD34+ subpopulations , 1995 .